VCELVericel Corporation

Healthcare

$40.12+27% 1Y

$40.12

$29.3452 weeks$47.81

Price

+27%1Y

End-of-day closes, not the intraday tick.

More going right than wrong

Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.

RyuScore 24 of 100: see how it is built

What they do

Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn care markets. We have a highly differentiated portfolio of cell therapy and specialty biologic products that combines innovations in biology with medical technologies. We were among the first companies to achieve commercial success in the complex field of cell therapies with treatments that use tissue engineering to regenerate skin and healthy knee cartilage.

In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR

P/E85.3

Market value$2.19B

1 year+27%

5 years-21%

Charts

As reported to the SEC, without any scoring.

Vericel Corporation (VCEL) reported revenue of $77M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with a gross margin of 73% and net income of $2.2M (2.8% of revenue). For the full year FY2025, revenue was $276M (+16% year on year) and net income $17M. Its largest product in Q2 2026 was MACI Implants And Kits at $66M, 86% of the disclosed total, well ahead of Epicel at 14%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

Jul 30, 202625 Blue Sky Drive Burlington, MA 01803.Earnings release · press release
May 18, 2026Effective May 18, 2026, the Board of Directors of Vericel Corporation, a Michigan corporation (the “Company”), approved an amendment to the Company’s bylaws.Charter/bylaw amendment or fiscal-year change · Form 8-K
May 7, 202664 Sidney Street Cambridge, MA 02139.Earnings release · press release